Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OP2113 intravenous and oral ATT pharmacokinetics study in healthy volunteers
NL-OMON48072Completed
- Sponsor
- OP2 Drugs
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of anethole trithione in myocardial infarction (MI) (3 arms), sponsored by OP2 Drugs. Primary endpoints: Pharmacokinetics of ATT and ATX after intravenous OP2113, Pharmacokinetics of ATT and ATX after oral ATT formulation and 1 more. Started Apr 2019; status: completed.
02
Drugs
anethole trithione
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NL-OMON48072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48072.